Advanced in Hepatitis B

Christoph Haefelin-Neumann

Hugstetter Str. 55, 
Freiburg, BW, DE 
Advanced in Hepatitis B
Hugstetter Str. 55, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Christoph Haefelin-Neumann practices in Freiburg, Germany. Mr. Haefelin-Neumann is rated as an Advanced expert by MediFind in the treatment of Hepatitis B. His top areas of expertise are Hepatitis, Hepatitis D, Hepatitis C, Hepatitis B, and Liver Transplant.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 22 articles in the study of Hepatitis B.

Gender
Male

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany
Other Locations
Hermann Herder Str, 11 79104, Freiburg, BW 79104, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3

126 Total Publications

T cells engineered to carry a high-affinity HBV-specific T cell receptor: a potent weapon against advanced HBV-related HCC.
T cells engineered to carry a high-affinity HBV-specific T cell receptor: a potent weapon against advanced HBV-related HCC.
Journal: Gut
Published: August 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Haefelin-Neumann's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile